Page 1: Executive summary

Introduction

Page 2: Types of diabetes

Page 3: Classification of the diabetes market

Page 4: Classes of anti-diabetic drugs

Market Overview

Page 5: Global Anti-Diabetic Pharmaceuticals Market - Overview, Size & Growth (Value: 2010-15e),

Page 6: Indian Anti-Diabetic Pharmaceuticals Market - Overview, Size & Growth (Value: 2010-2015e), Growth in Therapeutic segments

Page 7: Global Diabetes map

Drivers & Challenges

Page 8: Summary

Page 9-12: Drivers

Page13-14: Challenges

Government initiatives

Page 15: Government programmes

Market Value Chain, Regulation and Patents

Page 16: Pharmaceutical value chain

Page17: Phases of clinical trials

Page18-19: Drug regulations

Page 20: Regulatory framework

Page 21: List of patent approvals

Competition

Page 22: Competition overview

Page 23: Segmentation of players

Page 24: Market Competition - Porter'sFive Forces Analysis

Page 25: Summary- Major public players

Page 26-61: Major Public Players

Aventis Pharma Limited

Biocon Limited

Cipla Limited

Dr. Reddy's Laboratories Limited

GlaxoSmithKline Pharmaceuticals Limited

Merck Limited

Panacea Biotec Limited

Ranbaxy Laboratories Limited

Strides Arcolab Limited

Sun Pharmaceutical Industries Limited

Torrent Pharmaceuticals Limited

Wockhardt Limited

Page 62: Summary - Major Private Players

Page 63-74: Major Private Players

Bristol-Myers Squibb India Private Limited

Eli Lilly and Company (India) Private Limited

Novo Nordisk India Private Limited

Takeda Pharmaceuticals India Private Limited

Page 75: Recent Developments

Strategic Recommendation

Page 76: Strategic Recommendations

List of Charts & Figures

Market Overview

1. Anti Diabetic Pharmaceutical Market- Global Market Size and Growth (Value wise 2010 - 2015e)

2. Market Segmentation- Global (Percentage wise 2010 & 2015e)

3. Anti Diabetic Pharmaceutical Market - India Market Size and Growth (Value-Wise, 2010 - 2015e)

4. Growth in therapeutic segments (Percentage wise 2010)

5. Market Segmentation- India (Percentage wise 2010 & 2015e)

Drivers and Challenges

6. Increase in diabetic patients - India (Value wise 2010 - 2030e)

7. Demography- People >60 years in India (Value- Wise 2005 - 2020e)

Competition

8. Bubble chart: Competitive summary of major public and private companies

Except Takeda Pharmaceuticals India Private Limited

9. Financial Snapshot

10. Key Business segments (only Public Players)

11. Key Geographic segments (only Public Players)

Except GlaxoSmithKline Pharmaceuticals Limited

List of Tables

Market Value Chain, Regulation and Patent

1. Tabular representation of drugs approved in recent past (2008- 2010)

2. Tabular representation of regulatory framework of Indian Pharmaceutical Industry

3. Tabular representation of USFDA patent approvals

Competition

4. Segmentation of pharmaceutical companies

5. Company profiles (All companies)

a. Company information

b. Products and services

c. Key people

d. Key Financial Performance Indicators

e. Key Ratios

f. Business Highlights

Appendix

6. Ratio Calculations

Anti-diabetic pharmaceuticals market in India is one of the most lucrative diabetes markets in the world. Since India is the second largest diabetic pool in the world after China, the Indian market is characterized by a huge demand for anti-diabetic drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of diabetes cases, introduction of newer and better drugs, increasing aging population and introduction of diabetes insurance policies is helping the market to grow. The Indian Government, on its part, has introduced some diabetes control programmes. The market is expected to exhibit steady growth over the next few years.

The report begins with the introduction section which offers a brief classification of the different types of diabetes. It then gives a classification of the diabetes market, and then provides a brief description of different classes of anti-diabetic pharmaceuticals. The market overview section provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. It also provides a global diabetes map.

An analysis of the drivers explains the factors for growth of the industry including increasing diabetes cases, introduction of newer and better drugs, increasing aging population and increase in health insurance policies. The key challenges include price regulation in the insulin market, competition from use of complementary and alternative medicines and maintainence of a healthy lifestyle to avoid diabetes.

The government initiatives section gives a brief description of the different diabetes programmes undertaken by the Government.

A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals for anti-diabetic drugs.

The competition section gives overview of pharmaceutical companies in the country operating in the anti diabetic pharmaceutical and insulin segments along with segmentation of players in respect to production of oral drugs and insulin. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario.

The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares.